Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 29

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 1
Chunk 29
---
 withdraw any marketing or
    commercialization approvals we may receive and subject us to other penalties that could materially harm our business.

    ●
    If
    we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely
    affected.

    ●
    If
    we are not able to obtain and enforce patent protection for our technologies or product candidates, development and commercialization
    of our product candidates may be adversely affected.

    ●
    We
    or our licensors, or any future collaborators or a strategic partners may become subject to third party claims or litigation alleging
    infringement of patents or other proprietary rights or seeking to invalidate patents or other proprietary rights, and we may need
    to resort to litigation to protect or enforce our patents or other proprietary rights, all of which could be costly, time consuming,
    delay or prevent the development and commercialization of our product candidates, or put our patents and other proprietary rights
    at risk.

    ●
    If
    we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.

    ●
    We
    may be unable to obtain U.S. and/or foreign regulatory approval and, as a result, unable to commercialize our product candidates.

    ●
    Any
    drugs we develop may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform
    initiatives, thereby harming our business.

    ●
    Our
    ability to obtain services, reimbursement or funding from the federal government may be impacted by possible reductions in federal
    spending.

    ●
    If
    any of our product candidates receives marketing approval and we or others later identify undesirable side effects caused by the
    product candidate, our ability to market and derive revenue from the product candidates could be compromised.

    ●
    On
    December 31, 2024, the Company received a letter from Nasdaq stating that for the 30 consecutive business day period between
    November 15, 2024 to December 30, 2024 the Company’s common stock had failed to maintain a minimum closing bid price of $1.00
    per share, as required for continued listing pursuant to Nasdaq Listing Rule 5550(a)(2). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A),
    the Company has a grace period of 180 calendar days, or until June 30, 2025, to regain